New Drugs From Biogen, Octapharma, Alcon Passed By Europe’s CHMP

Europe’s top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended a new long-acting beta-interferon in MS, a highly pure recombinant Factor VIII, and a new combination eye-drop for glaucoma, but confirmed its previous rejections of Novartis’s heart failure therapy, Teva’s oral MS medicine and AB Science’s pancreatic cancer product.